Table 1.

Best overall response rate in the successfully karyotyped patients treated with idelalisib/rituximab per IRC assessment

	Idelalisib+rituximab
	CK-positive, N = 26	CK-negative, N = 37
ORR, n (%)a	21 (80.8)	33 (89.2)
95% CIb	60.6, 93.4	74.6, 97.0
Complete response	0	0
Partial response	21 (80.8)	33 (89.2)
Stable disease	3 (11.5)	2 (5.4)
Progressive disease	1 (3.8)	0
Not evaluable	1 (3.8)	2 (5.4)
Odds ratio for ORRc	0.5
95% CI for odds ratio	0.1, 2.1
p-value	0.3509

CI confidence interval, CK complex karyotype, IRC Independent Review Committee, ORR overall response rate

^aORR is the percentage of patients who had best overall response of complete response or partial response

^b95% CI for ORR is based on the exact method

^cOdds ratio and 95% CI are calculated without any adjustment